Heart failure is not a sudden stopping of the heart but a chronic condition in which the heart muscle can no longer pump blood efficiently enough to meet the body’s demands. It is the most rapidly growing cardiovascular health burden worldwide, and it comes in several forms that differ at the cellular level and respond to different treatments.1PubMed Central. Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding Understanding what heart failure actually involves, how it is classified, and which therapies have the strongest evidence behind them matters for anyone living with the diagnosis or caring for someone who is.
What Goes Wrong in the Failing Heart
A healthy heart squeezes blood out with each beat and then relaxes to refill. Heart failure disrupts one or both of those actions. When the squeezing power weakens, doctors call it heart failure with reduced ejection fraction, or HFrEF. When the heart squeezes normally but stiffens so it cannot fill properly, that is heart failure with preserved ejection fraction, or HFpEF. A middle category, sometimes called mildly reduced ejection fraction, sits between the two.2PubMed Central. Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding The distinction is not academic. HFrEF and HFpEF develop through different cellular pathways, attract different complications (atrial fibrillation, for instance, is more common in HFpEF), and respond differently to medications.3PubMed Central. Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis
Regardless of the type, the body senses the drop in blood flow and tries to compensate. The sympathetic nervous system ramps up, raising heart rate and constricting blood vessels. The kidneys activate a hormonal cascade called the renin-angiotensin-aldosterone system, which retains salt and water to increase blood volume. In the short term these responses prop up circulation, but when they stay switched on for months or years they pile extra stress on the heart, damage blood vessels, and accelerate the disease.4PubMed Central. Neurohormonal activation in heart failure with reduced ejection fraction Blocking those overactive hormonal systems has become the foundation of modern heart failure treatment.
Common Causes
Coronary artery disease is the leading cause of heart failure in the Western world.5PubMed Central. Overview of the relationship between ischemia and congestive heart failure Blocked or narrowed arteries starve portions of the heart muscle of oxygen. Over time this triggers scarring and remodeling, where the heart gradually changes shape and enlarges, worsening its pumping ability. The damage is not always limited to large coronary blockages; dysfunction in the tiny blood vessels of the heart muscle can also reduce blood flow enough to cause heart failure even without a dramatic plaque.6PubMed Central. Ischemic Heart Disease and Heart Failure: Role of Coronary Ion Channels
Plenty of people develop heart failure without any coronary disease at all. Longstanding high blood pressure forces the heart to work harder until the muscle thickens and stiffens. Valve diseases, viral infections of the heart muscle, heavy alcohol use, and inherited genetic mutations can all lead to cardiomyopathy. An estimated 40 percent of familial dilated cardiomyopathy cases have an identifiable genetic cause, and some of the implicated genes also raise the risk of dangerous arrhythmias.7PubMed Central. Genetics of Dilated Cardiomyopathy
Cancer treatment is another increasingly recognized trigger. Anthracycline chemotherapy drugs, used across many solid and blood cancers, carry a dose-dependent risk of heart muscle damage. The reported rate of clinical heart failure sits around two to four percent with low-dose regimens, though subtler cardiac injury detected by blood biomarkers occurs in up to about a third of patients.8PubMed Central. Heart Failure in Relation to Anthracyclines and Other Chemotherapies The toxicity can surface during treatment, weeks later, or even months after the last dose, and in some cases the damage is irreversible.9PubMed Central. Chemotherapy-induced Cardiotoxicity Risk goes up with higher cumulative doses, prior heart disease, chest radiation, and extremes of age.10PubMed Central. Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management
How Doctors Diagnose It
Shortness of breath, fatigue, and ankle swelling are the classic complaints, but those symptoms overlap with many other conditions. Blood tests for B-type natriuretic peptide (BNP) and a related fragment called NT-proBNP have become central to the diagnostic workup. Both are released by heart muscle cells under stress. Systematic reviews have found that both markers carry a high degree of diagnostic accuracy for heart failure, whether the presentation is acute or chronic.11Clinical Chemistry. Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review In emergency departments, a BNP level at or above 100 pg/mL has shown sensitivity above 90 percent for heart failure in patients with significant breathlessness.12PubMed Central. Diagnostic accuracy of plasma brain natriuretic peptide for evaluation of dyspnea NYHA-III and NYHA-IV in emergency department of tertiary care hospital
These peptide levels are not a standalone diagnosis. An echocardiogram remains the workhorse imaging test, measuring how well the heart squeezes and fills and sorting patients into the HFrEF, HFmrEF, or HFpEF categories. What the blood tests do well is help clinicians decide quickly whether heart failure is likely, track how a patient is responding to treatment over time, and flag worsening disease before symptoms spike.13PubMed Central. Clinical Significance of B-type Natriuretic Peptide in Heart Failure
Drug Treatments That Have Changed the Outlook
Modern heart failure pharmacotherapy works largely by tamping down the overactive hormonal stress responses described earlier. Several drug classes now have strong trial evidence behind them, and the trend over the past decade has been toward using them in combination rather than sequentially.
Sacubitril/valsartan (sold as Entresto) combines a blocker of the renin-angiotensin system with a drug that boosts the body’s own protective natriuretic peptides. A meta-analysis of randomized trials found it reduced heart failure hospitalizations by about 20 percent and all-cause mortality by roughly 11 percent compared with older angiotensin blockers alone.14PubMed Central. Efficacy and safety of sacubitril/valsartan in heart failure compared to renin–angiotensin–aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials The mortality benefit is clearest in patients whose ejection fraction is 40 percent or below; in those with higher ejection fractions, hospitalizations still drop but the survival advantage narrows.15PubMed Central. Sacubitril/Valsartan vs ACE Inhibitors or ARBs: A Systematic Review and Meta-Analysis of Randomized Trials Real-world data have confirmed similar directional benefits, with one large observational study showing a 20 percent lower risk of death compared with conventional therapy.16PubMed Central. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction
SGLT2 inhibitors (empagliflozin and dapagliflozin) were originally developed for diabetes, but large randomized trials showed they prevent cardiovascular events and cut the risk of death and hospitalization from heart failure, and the benefit extends to people who do not have diabetes at all.17PubMed Central. SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms The drugs appear to work through several pathways at once: reducing fluid overload, shifting the heart’s energy metabolism toward more efficient fuels, easing inflammation, and protecting ion balance in heart cells. Their rapid adoption into guidelines for both HFrEF and HFpEF has been one of the biggest shifts in heart failure management in years.
Mineralocorticoid receptor antagonists such as spironolactone and eplerenone target the aldosterone piece of the hormonal cascade. In patients with HFrEF, spironolactone has been shown to lower markers of heart muscle scarring and fibrosis. In patients with HFpEF and mild symptoms, it improved the heart’s ability to relax during filling and reduced heart size and natriuretic peptide levels.18Oxford Academic. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases These drugs carry a meaningful risk of high potassium levels, especially in patients whose kidneys are already compromised, so careful lab monitoring is part of the package.
Devices and Mechanical Support
When medications are not enough, device therapy enters the picture. Cardiac resynchronization therapy (CRT) uses a specialized pacemaker to coordinate the timing of the heart’s contractions. In patients whose heart chambers beat out of sync, CRT can substantially improve pumping efficiency, but the benefit depends on the presence of that electrical dyssynchrony; patients without it tend not to improve.19PubMed. Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation Emerging trial data suggest that when CRT successfully corrects the dyssynchrony pattern, patients are less likely to experience ongoing deterioration.20European Heart Journal. Mechanical dyssynchrony and response to cardiac resynchronization therapy in heart failure patients with right ventricular pacing: a pre-specified subgroup analysis of the BUDAPEST CRT Upgrade trial
For patients with severe, end-stage heart failure, a left ventricular assist device (LVAD) offers a more drastic intervention. The device is a surgically implanted mechanical pump that helps the weakened ventricle push blood to the body. It was once used almost exclusively to keep patients alive while they waited for a transplant, but a growing share of recipients now receive it as permanent, “destination” therapy. In a cohort study of the latest magnetically levitated pump, five-year mortality was about 38 percent overall. Among patients who made it through the initial surgical hospitalization without certain complications, that figure dropped to roughly 23 percent.21PubMed. Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device Those numbers represent real progress, though the therapy is not without burdens: about 30 percent of destination-therapy recipients experienced either death or persistently poor quality of life in an earlier registry analysis.22PubMed Central. Frequency of Poor Outcome (Death or Poor Quality of Life) After Left Ventricular Assist Device for Destination Therapy: Results From the INTERMACS Registry Selecting the right patient at the right time remains one of the hardest decisions in advanced heart failure care.
When the Kidneys Get Pulled In
Heart failure and kidney failure feed off each other in a loop that cardiologists call cardiorenal syndrome. The kidneys depend on steady blood flow and pressure from the heart, and the heart depends on the kidneys to regulate fluid volume and clear waste. When the heart decompensates acutely, reduced forward flow and rising venous congestion can cause an abrupt drop in kidney filtering capacity.23PubMed Central. The cardiorenal syndrome: making the connection This kidney injury then limits the body’s ability to shed excess fluid, which worsens the heart’s workload further. The relationship also runs the other direction: chronic kidney disease can cause heart failure through fluid overload, toxin accumulation, and systemic inflammation.24PubMed Central. Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimens-From a Cardiologist’s View In practice, many heart failure patients live with some degree of kidney impairment, and their treatment plans have to balance diuretic use, blood pressure control, and medication doses that are safe for both organs simultaneously.
Iron Deficiency and Sleep Apnea
Two comorbidities deserve special mention because they are common in heart failure, worsen outcomes, and are treatable on their own terms.
Iron deficiency affects a large share of heart failure patients, often without causing frank anemia. The heart and skeletal muscles are highly dependent on iron for energy production, and when stores run low, exercise tolerance plummets. Trials of intravenous iron (ferric carboxymaltose) in iron-deficient heart failure patients showed that treatment maintained peak oxygen consumption while it declined in untreated controls, and improved functional class and patients’ own assessment of how they felt.25PubMed Central. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency Intravenous iron also cut heart failure hospitalizations substantially in one trial, with a hazard ratio suggesting a roughly 60 percent reduction.26PubMed Central. Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients Checking ferritin and transferrin saturation has become a routine part of heart failure workups because the fix is straightforward and the payoff is real.
Central sleep apnea with a distinctive waxing-and-waning breathing pattern, called Cheyne-Stokes respiration, is common in heart failure. It is driven partly by the same sympathetic nervous system overdrive that worsens heart failure itself: repeated drops in oxygen and frequent arousals from sleep keep adrenaline levels high around the clock. Most studies have linked this breathing pattern to higher mortality in heart failure, though the research community has debated whether the apnea itself is doing harm or simply reflecting more advanced disease.27PubMed. Central sleep apnea and Cheyne-Stokes respiration Either way, screening for sleep-disordered breathing and treating it when found is part of thorough heart failure care.
Exercise, Sodium, and the Lifestyle Conversation
People diagnosed with heart failure often assume they should avoid physical activity. The evidence says the opposite. Exercise training and formal cardiac rehabilitation are safe and produce meaningful improvements in quality of life, functional capacity, and rates of hospitalization for heart failure.28PubMed. Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Panel Programs typically combine moderate aerobic exercise with resistance training, supervised at first and then transitioned to home-based routines. The improvements in day-to-day function are among the most noticeable changes patients report across all heart failure therapies.
Sodium restriction has been standard advice for decades, but the evidence behind it has grown murkier. A systematic review and meta-analysis of randomized trials found that cutting sodium did not reduce the risk of death, hospitalization, or a combination of the two.29PubMed. Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials A separate meta-analysis pointed in an even more unsettling direction, finding that sodium restriction was associated with a higher risk of a composite bad outcome.30PubMed Central. Role of dietary sodium restriction in chronic heart failure: systematic review and meta-analysis The current expert view is nuanced: aggressive sodium restriction should not be applied across the board, but individual patients with fluid retention issues might still benefit, particularly for symptom relief and quality of life rather than hard clinical endpoints.31PubMed. The current state of evidence for sodium and fluid restriction in heart failure If your doctor tells you to watch your salt, it is worth asking what the specific goal is and how tightly they want you to restrict.
Remote Monitoring With Implantable Sensors
One of the most frustrating aspects of heart failure is that fluid can build up in the lungs for days before a patient feels noticeably worse. By the time symptoms become obvious, an emergency hospitalization is often unavoidable. Implantable pulmonary artery pressure sensors, like the CardioMEMS device, aim to close that gap. A small sensor placed in a branch of the pulmonary artery transmits daily pressure readings wirelessly. Clinicians can then adjust diuretics and other medications based on pressure trends, well before symptoms escalate.
Randomized trials have shown that this approach reduces heart failure hospitalizations. A meta-analysis found that remote pressure monitoring cut the hospitalization rate by roughly 28 percent, with a time-to-event analysis suggesting an even larger reduction in the risk of a first hospitalization.32PubMed Central. Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association ( HFA ) of the ESC The benefit held regardless of whether the patient had reduced or preserved ejection fraction. This technology is still relatively new and not universally available, but it represents a shift toward proactive, data-driven management rather than waiting for crises.
Palliative Care Is Not Just for the End
Palliative care has an image problem in heart failure. Many patients and families hear the word “palliative” and think it means giving up on treatment. In reality, palliative care specialists work alongside the cardiology team, often starting well before the disease reaches its final stages. Their focus is on controlling the symptoms that heart failure medications do not always reach: persistent breathlessness, pain, fatigue, depression, and the anxiety that comes with a condition whose trajectory is unpredictable.
Studies have shown that integrating palliative care with standard heart failure management improves symptom control, quality of life, and communication between patients, families, and medical teams. Caregiver satisfaction goes up and caregiver anxiety goes down.33PubMed. Palliative Care Across the Spectrum of Heart Failure Palliative care teams also help with practical decisions: when to deactivate an implantable defibrillator, how aggressively to pursue hospital readmissions, and how to align treatment intensity with a patient’s own goals.34PubMed Central. Palliative care and hospice in advanced heart failure Early involvement tends to make those conversations less rushed and less fraught than waiting until a crisis forces them.
The Gut Microbiome Connection
A less expected area of heart failure research involves the bacteria in your gut. In heart failure, poor blood flow to the intestines and chronic congestion in the gut wall alter the microbial ecosystem living there. One metabolite that has attracted particular attention is trimethylamine N-oxide, or TMAO. Gut bacteria produce TMAO from nutrients found in red meat, eggs, and certain fish. TMAO activates inflammatory pathways, triggers the release of inflammatory signaling molecules, and promotes dysfunction in the cells lining blood vessels, all of which raise cardiovascular risk.35PubMed Central. The association between the gut microbiota metabolite trimethylamine N-oxide and heart failure
Whether TMAO is a direct driver of heart failure progression or primarily a marker of an unhealthy gut ecosystem is still being sorted out. No approved therapy targets the gut microbiome for heart failure specifically, and probiotic supplements have not shown convincing clinical benefits in this context. Still, the research points toward a broader truth: heart failure is not just a plumbing problem in the chest. It is a systemic condition that reaches into the kidneys, the gut, the muscles, the brain, and the immune system. Effective management means paying attention to the whole picture, not just the ejection fraction on an echo report.
Gene Therapy and Future Directions
Among the more ambitious research efforts is gene therapy aimed at a protein called SERCA2a. This protein helps the heart muscle relax between beats by pulling calcium back into storage inside heart cells. In heart failure, SERCA2a levels drop, and the heart becomes stiffer and less efficient. Preclinical work using viral vectors to deliver the SERCA2a gene directly into heart tissue has enhanced contractile function and reduced mortality in animal models.36PubMed Central. SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope Human trials have been more complicated, and no gene therapy is approved for heart failure today. But the concept of correcting a specific molecular defect rather than simply blocking a harmful hormonal pathway represents a fundamentally different approach, and one that several research groups continue to pursue.